Clinical Trial Update: Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation and Food Effect [Phase 1]

View source ↗

Summary

A Phase 1 study from GlaxoSmithKline evaluated the relative bioavailability of a pediatric PfOS powder-for-suspension formulation and the effect of food on its …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Thrombocytopenic Purpura

Snippet

Sponsor: GlaxoSmithKline | Conditions: Purpura, Thrombocytopaenic, Idiopathic | Phase 1 | Status: COMPLETED